(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 March 2007 (08.03.2007)

PCT

(10) International Publication Number
WO 2007/027713 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
C12N 15/13 (2006.01)

(21) International Application Number:
PCT/US2006/033763

(22) International Filing Date: 28 August 2006 (28.08.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/713,433 31 August 2005 (31.08.2005) US
60/713,478 31 August 2005 (31.08.2005) US

(71) Applicant *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GLINIAK, Brian** [US/US]; 219 36th Avenue East, Seattle, Washington 98112 (US). **YANG, Xiao-dong** [US/US]; 2833 Bryant Street, Palo Alto, California 94306 (US). **WONG-MADDEN, Sharon** [US/US]; 6252 167th Avenue, S.e., Bellevue, Washington 98006 (US). **FOLTZ, Ian** [CA/CA]; 2108 Knightswood Place, Burnaby, British Columbia V5A 4B9 (CA). **FENG, Xiao** [US/US]; 135 Red Cedar Lane, Union City, California 94587 (US). **FITCH, Alison** [CA/CA]; #201-2525 Waterloo St., Vancouver, British Columbia V6R 3H6 (CA). **FOSTER, Stephen** [US/US]; 2956 Wauneta Street, Newbury Park, California 91320 (US). **KETCHEM, Randall, R.** [US/US]; 6332 152nd Street, Snohomish, Washington 98269 (US).

(74) Agent: **BARKER, M., Paul**; Finnegan, Henderson, Farabow, Garrett & Dunner LLP, 901 New York Avenue, N.W., Washington, D.C., District Of Columbia 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
28 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES

(57) Abstract: Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand ("TRAIL") Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

WO 2007/027713 A3